Company Overview of Immunocore Limited
Immunocore Limited, a bio-technology company, discovers and develops bio-therapeutics for the treatment of cancer, viral diseases, and autoimmune diseases. It offers T cell receptors, a peptide antigen that presented on the surface of cells by human leukocyte antigen molecules; and IMCgp100, a novel bi-specific immunotherapeutic for the treatment of malignant melanoma. Immunocore Limited was formerly known as Avidex Limited and changed its name to Immunocore Limited in October 2008. The company was founded in 1999 and is based in Abingdon, United Kingdom with an additional office in Conshohocken.
91 Park Drive
Abingdon, OX14 4RY
Founded in 1999
Key Executives for Immunocore Limited
Founder and Chief Scientific Officer
Chief Business Officer and Director
Compensation as of Fiscal Year 2016.
Immunocore Limited Key Developments
Immunocore's IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
Mar 30 16
Immunocore announced that it has recruited the first patient into a Phase I monotherapy trial of its lead programme, IMCgp100, for the treatment of uveal melanoma. Uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye, comprises approximately 3% of all melanomas, and is the primary intraocular malignancy of the adult eye. There are currently no effective treatments on the market for this debilitating disease. The trial will include three Phase I escalation cohorts to determine the optimal dose for the pivotal Phase II study, which is expected to start in 2016, and will take place at a number of centres around the world. The US Food and Drug Administration (FDA) in January 2016 granted Orphan Drug Designation to IMCgp100 for the treatment of uveal melanoma. Orphan Drug status qualifies Immunocore for a number of development incentives to enable rapid progress in the clinical development of IMCgp100 in advanced uveal melanoma, its most advanced therapeutic. The Orphan Drug Designation programme provides orphan status to drugs and biologics, defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders where the prevalence of the condition affects no more than 200,000 people in the US. IMCgp100 is Immunocore's wholly-owned and most advanced ImmTAC (Immune mobilizing mTCR Against Cancer), currently in Phase I/IIa clinical trials for the treatment of late stage metastatic melanoma. Promising results from the Phase I/IIa clinical trial of IMCgp100 in advanced cutaneous and uveal melanoma patients demonstrated that responses were durable, with five objective responses to date, two of which are partial responders in patients with uveal melanoma. To date, more than 85 patients have been treated with IMCgp100.
Immunocore Receives US Food and Drug Administration Orphan Drug Designation to its IMCgp100
Jan 25 16
Immunocore announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead programme, IMCgp100, for the treatment of uveal melanoma. The Orphan Drug status qualifies Immunocore for a number of development incentives and will enable Immunocore to receive fast track registration for IMCgp100, its lead ImmTAC (Immune mobilising mTCR Against Cancer) therapeutic. Uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye, comprises approximately 3% of all melanomas, and is the primary intraocular malignancy of the adult eye. There are currently no effective treatments on the market for this debilitating disease. For a drug to qualify for orphan drug designation both the drug and the disease must meet certain criteria specified in the Orphan Drug Act (ODA) and FDA's implementing regulations at 21 CFR Part 316. IMCgp100 is Immunocore’s wholly-owned and most advanced ImmTAC, currently in Phase IIa clinical trials for the treatment of late stage cutaneous and uveal melanoma. To date, more than 85 patients have been treated with IMCgp100. IMCgp100 was also accepted last year to participate in the European Medicines Agency's (EMA) Adaptive Pathways Pilot Programme, part of the EMA's strategy of providing timely access for patients to new medicines to treat serious conditions with high unmet medical need.
Immunocore Limited Starts Phase Ib/II Combination Trial for the Treatment of Metastatic Cutaneous Melanoma
Jan 20 16
Immunocore Limited announced that it has started a Phase Ib/II combination trial for the treatment of metastatic cutaneous melanoma. The trial will evaluate IMCgp100, Immunocore's lead ImmTAC (Immune Mobilising Monoclonal T-Cell Receptor Against Cancer), in combination with durvalumab and tremelimumab, the investigational immunotherapies of MedImmune, the global biologics research and development arm of AstraZeneca. The open label, four arm, randomized Phase Ib/II trial will explore IMCgp100 paired respectively with durvalumab and tremelimumab as well as investigating all three immunotherapy agents together. The primary goal of the combination trials will be to assess the safety and efficacy of the different combinations. Immunocore is responsible for conducting the trial. The companies announced the formation of this combination partnership in April 2015 and also have a pre-existing research collaboration and licensing agreement, announced in January 2014, to develop novel cancer therapies using Immunocore's ImmTAC technology.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 4, 2016